The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Karyopharm Therapeutics
 
Leadership - Karyopharm Therapeutics; SeraCare
Stock and Other Ownership Interests - Karyopharm Therapeutics; SeraCare
Honoraria - Advaxis; AstraZeneca; Cerulean Pharma; Clovis Oncology; Novocure; Pfizer; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; BIOCAD; Cerulean Pharma; Clovis Oncology; Genmab; Karyopharm Therapeutics; Novocure; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim France (Inst); Pfizer (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro
 
Speakers' Bureau - GlaxoSmithKline; MSD
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD; PharmaMar
Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.
 
Vicky Makker
Consulting or Advisory Role - ArQule; Clovis Oncology; DualityBio; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; ITeos Therapeutics; Kartos Therapeutics; Karyopharm Therapeutics; Lilly; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Eisai (Inst); Faeth Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Eisai; Karyopharm Therapeutics; Merck
Other Relationship - IBM
 
Jose Alejandro Perez-Fidalgo
Consulting or Advisory Role - Ability Pharma; Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Roche; Tesaro
Speakers' Bureau - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; Ipsen; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline (Inst); Pharmamar (Inst)
Patents, Royalties, Other Intellectual Property - Pending patent
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca Spain; Novartis
 
Alice Bergamini
Travel, Accommodations, Expenses - PharmaMar; Tesaro
 
Daniel Lewis Spitz
No Relationships to Disclose
 
Toon Van Gorp
Consulting or Advisory Role - AstraZeneca (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
Jalid Sehouli
Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro
 
Jaroslav Klat
No Relationships to Disclose
 
Tamar Perri
No Relationships to Disclose
 
Amit M. Oza
(OPTIONAL) Uncompensated Relationships - Ozmosis Research
 
Estrid Vilma Solyom Hogdall
No Relationships to Disclose
 
Jason A. Konner
Consulting or Advisory Role - AstraZeneca; Clovis Oncology
Research Funding - Immunogen
 
Eva M. Guerra
Honoraria - GlaxoSmithKline/Tesaro; Merck; PharmaMar; Roche
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro; PharmaMar; Roche
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche
Expert Testimony - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche; Tesaro
 
Francesco Raspagliesi
No Relationships to Disclose
 
Stephanie Henry
Consulting or Advisory Role - AstraZeneca; BMSi; Gilead Sciences; Merck; MSD Oncology; Novartis; Sanofi; Sanofi
Travel, Accommodations, Expenses - MSD Oncology; Roche
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Jeronimo Martinez Garcia
Consulting or Advisory Role - PharmaMar
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD; PharmaMar
 
Brian M. Slomovitz
Consulting or Advisory Role - Agenus; AstraZeneca; Clovis Oncology; Eisai; EQRx; Genentech; GlaxoSmithKline; GOG Foundation; Incyte; Merck; Myriad Genetics; Nuvation Bio; Onconova Therapeutics; Regeneron
 
Sharon Shacham
No Relationships to Disclose
 
Mansoor Raza Mirza
No Relationships to Disclose
 
Ignace Vergote
Consulting or Advisory Role - Agenus; Akesobio - China; Amgen (Inst); AstraZeneca; Britol Myers Squibb; Carrick Therapeutics (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai; Elevar Therapeutics; Genmab (Inst); GlaxoSmithKline; Immunogen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Mersana; Millennium (Inst); MSD; Novartis; Novocure; Octimet (Inst); Oncoinvent; Roche; Seagen; Sotio; Verastem (Inst); Zentalis
Research Funding - Amgen (Inst); Genmab (Inst); Oncoinvent (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD/Merck; Roche; Tesaro